Literature DB >> 1893776

Development of antiviral therapy for chronic infection with hepatitis B virus.

P L Marion1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1893776     DOI: 10.1007/978-3-642-76015-0_8

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


× No keyword cloud information.
  6 in total

1.  Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.

Authors:  J M Cullen; D H Li; C Brown; E J Eisenberg; K C Cundy; J Wolfe; J Toole; C Gibbs
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

2.  Duck hepatitis B virus infection of hepatocytes is not dependent on low pH.

Authors:  R J Rigg; H Schaller
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

3.  Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro.

Authors:  G Civitico; T Shaw; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus.

Authors:  T Shaw; P Amor; G Civitico; M Boyd; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 5.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

6.  Hepatitis B virus surface antigen binds to apolipoprotein H.

Authors:  H Mehdi; M J Kaplan; F Y Anlar; X Yang; R Bayer; K Sutherland; M E Peeples
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.